Détails du produit
Synonyms
NKG2A & CD94
Source
Human NKG2A&CD94 Protein, His Tag (NC4-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 113 - Leu 233 (NKG2A) & Asp 57 - Ile 179 (CD94) (Accession # P26715-1 (NKG2A) & Q13241-1 (CD94)).
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 30.7 kDa. The protein migrates as 40-55 kDa and 65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Human NKG2A&CD94 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Human NKG2A&CD94 Protein, His Tag (Cat. No. NC4-H52H3) at 2 μg/mL (100 μL/well) can bind Anti-NKG2A Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
NK cell lectin-like receptor subfamily C member 1
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
6 Détails
- Étape de développement la plus élevée:
Phase 3 Clinical



















